PDCD1 and non-small cell lung carcinoma: Studies have shown that gut microbiota plays an important role in the response of NSCLC patients to anti-PD-1 therapy, and that gut microbiota diversity is significantly increased in patients who respond to anti-PD-1 therapy (47).